International Stem Cell (ISCO) is an early-stage cell therapy company currently in Phase I/IIa clinical trials to treat Parkinson’s disease (PD). In addition, ISCO sells skincare and biomedical supplies to the market, generating $8m in sales and $1.7m in underlying operating profit in 2015. The commercial businesses provide a floor under ISCO’s current valuation, creating an essentially free option on the PD candidate.
16 May 2016
Seeking a better treatment for Parkinson's
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Seeking a better treatment for Parkinson's
- Published:
16 May 2016 -
Author:
Beth Senko -
Pages:
12
International Stem Cell (ISCO) is an early-stage cell therapy company currently in Phase I/IIa clinical trials to treat Parkinson’s disease (PD). In addition, ISCO sells skincare and biomedical supplies to the market, generating $8m in sales and $1.7m in underlying operating profit in 2015. The commercial businesses provide a floor under ISCO’s current valuation, creating an essentially free option on the PD candidate.